目的：观察二甲胶囊抗肝纤维化、治疗肝硬化(代偿期)的临床疗效和安全性。
Objective: To observe clinical effect and safety that Erjia capsule treated cirrhosis of liver.
结论腹主动脉结扎大鼠心房纤维化程度增加，P波时限增宽，IACT延长，心房有效不应期没有改变。
Conclusion The extent of atrial fibro sis was increased in abdominal aorta banded rats. Although longer P wave duration and IACT are present, there is no change in atrial effective refractory period.
恢复期和慢性期则伴有明显的心肌纤维化，部分患者最后进展为扩张型心肌病和严重的充血性心力衰竭。
The heart of patients always had a fibrosis at the recovery or chronic period. Some people developed into dilated cardiomyopathy at last.
免疫耐受期患者只有很轻或没有肝纤维化进展，而免疫清除期是肝硬化的高发时期。
Immune-tolerant phase patients only very light or no liver fibrosis progression, and immune clearance period is liver cirrhosis of high-risk period.
免疫耐受期患者只有很轻或没有肝纤维化进展，而免疫清除期是肝硬化的高发时期。
Immune-tolerant phase patients only very light or no liver fibrosis progression, and immune clearance period is liver cirrhosis of high-risk period.
应用推荐